Iron Phosphate

Iron phosphate (FePO₄) is an inorganic iron compound delivering ferric iron (Fe³⁺) that must be reduced to ferrous iron (Fe²+) by duodenal cytochrome B (DcytB) before intestinal absorption via divalent metal transporter 1 (DMT1). Unlike ferrous sulfate, iron phosphate has extremely poor bioavailability in humans and lacks clinical evidence supporting its use as a therapeutic iron supplement.

Origin & History

Iron phosphate (FePO₄) is an inorganic mineral compound with a molecular weight of 150.82 g/mol that appears as a yellowish-brown to pale beige powder. It is synthetically produced through chemical reactions, typically by combining sodium phosphate with ferric chloride or ferric citrate.

Historical & Cultural Context

The research dossier contains no information regarding historical or traditional use of iron phosphate in any traditional medicine system or cultural context.

Health Benefits

• No clinical benefits documented - the provided research contains no human studies or clinical trials evaluating iron phosphate supplementation
• Theoretical iron source - may provide Fe³⁺ ions for iron metabolism, though no clinical evidence supports this
• No peer-reviewed evidence available for specific health outcomes
• No meta-analyses or RCTs found in the research dossier
• Evidence quality: None - only chemical property data available

How It Works

Iron phosphate releases ferric iron (Fe³⁺) ions that must first be reduced to ferrous iron (Fe²⁺) by the brush-border enzyme duodenal cytochrome B (DcytB) in the proximal duodenum. Ferrous iron is then transported across the enterocyte apical membrane via divalent metal transporter 1 (DMT1, also known as SLC11A2), enters systemic circulation bound to transferrin, and is utilized for hemoglobin synthesis and incorporation into iron-dependent enzymes such as cytochrome P450 and ribonucleotide reductase. The strong phosphate binding in FePO₄ significantly limits Fe³⁺ solubilization in the gastrointestinal tract, making the reduction and absorption steps far less efficient than with soluble ferrous salts.

Scientific Research

The research dossier contains no clinical trials, randomized controlled trials, meta-analyses, or PubMed citations evaluating iron phosphate in human subjects. The available sources focus exclusively on the compound's chemical properties and industrial applications rather than biomedical efficacy.

Clinical Summary

No published randomized controlled trials or clinical studies have specifically evaluated iron phosphate as an oral supplement in humans for iron deficiency or iron deficiency anemia. Animal model data and in vitro dissolution studies consistently demonstrate that iron phosphate has markedly lower solubility and bioavailability compared to ferrous sulfate and ferrous fumarate, the established clinical standards. A 2004 food fortification review by Hurrell et al. classified iron phosphate as having very low relative bioavailability (~4% compared to ferrous sulfate), primarily noting its use as a food additive rather than a therapeutic supplement. The current absence of human clinical trial data means no evidence-based dosing recommendations, efficacy endpoints, or comparative effectiveness conclusions can be drawn.

Nutritional Profile

Iron Phosphate (FePO₄) is an inorganic mineral compound with the following compositional profile: Iron (Fe³⁺) content approximately 37% by molecular weight (based on molecular weight of FePO₄ = 150.82 g/mol, with Fe contributing ~55.85 g/mol); Phosphorus (P) content approximately 20.5% by molecular weight. Contains no macronutrients (zero protein, zero fat, zero carbohydrates, zero fiber). Contains no vitamins or organic bioactive compounds. As a pure mineral salt, it provides two nutritionally relevant minerals — iron and phosphate — in fixed stoichiometric ratio. Bioavailability is notably poor: Fe³⁺ (ferric iron) in phosphate-bound form has very low gastrointestinal solubility compared to ferrous (Fe²⁺) salts such as ferrous sulfate or ferrous fumarate; absorption requires reduction to Fe²⁺ by duodenal cytochrome B (Dcytb) in the intestinal brush border, a rate-limiting step. Relative bioavailability compared to ferrous sulfate is estimated at less than 50% in most studies, with some estimates as low as 14–30% depending on gastric pH and concurrent dietary factors. Phosphate component (PO₄³⁻) is absorbed via sodium-phosphate cotransporters in the small intestine, but bioavailability from this compound is not independently characterized. No caloric value. Used primarily as a food fortification agent and pesticide (slug/snail bait) rather than a dietary supplement, meaning typical human exposure through food fortification is at trace levels (1–8 mg elemental iron per serving in fortified products).

Preparation & Dosage

No clinically studied dosage ranges are available in the provided research. The sources contain no information on standardized extract dosages, powder formulations, or clinical dosing protocols for human use. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified due to lack of clinical data

Safety & Interactions

Iron phosphate is generally regarded as low-risk for acute toxicity due to its poor solubility, meaning systemic iron overload from oral intake is unlikely; however, this same property renders it ineffective as a therapeutic supplement. High-dose supplemental iron in any form can cause gastrointestinal side effects including nausea, constipation, and dark stools, though these are less commonly reported with poorly absorbed iron forms. Iron supplements broadly interact with tetracycline and fluoroquinolone antibiotics, levothyroxine, levodopa, and antacids containing calcium or magnesium, all of which can further reduce already limited iron absorption. Iron supplementation is contraindicated in hemochromatosis, hemosiderosis, and other iron overload disorders; pregnant women requiring iron supplementation should consult a physician and use clinically validated forms such as ferrous sulfate or ferric carboxymaltose.